Dr Amy Anderson
Senior Research Associate
- Email: firstname.lastname@example.org
- Telephone: +44 (0) 191 208 8044
- Fax: +44 (0) 191 208 5455
- Personal Website: http://www.ncl.ac.uk/biomedicine/research/groups/musculoskeletal.htm
- Address: Musculoskeletal Research Group,
Institute of Cellular Medicine,
4th Floor Catherine Cookson Building,
The Medical School,
Newcastle upon Tyne,
I did my PhD at Imperial College London identifying host genetic loci responsible for the outcome of Helicobacter pylori infection. After my PhD I remained at Imperial College and worked as a Research Assistant studying seasonal changes in the suppressive capacity of Tregs in hayfever sufferers. I moved to Newcastle University in 2006 and have since worked as a Research Associate.
Since coming to Newcastle I have been involved in a number of projects focusing on the development of biomarkers for the diagnosis of rheumatoid arthritis in addition to development of novel immunotherapies for rheumatoid arthritis, with a particular interest in therapeutic tolerance induction.
The main project I having been working on, in collaboration with Professor John Isaacs and Dr Catharien Hilkens, is the development of autologous tolerogenic dendritic cells for the treatment of rheumatoid arthritis. This project is now in phase I clinical trial (AuToDeCRA study, funded by Arthritis Research UK).
I have recently been involved in a project, in collaboration with Professor John Isaacs and Dr Arthur Pratt, to identify a potential transcriptional biomarker for the early diagnosis of seronegative rheumatoid arthritis. We have demonstrated that interleukin-6 and downstream STAT3 signalling are potential therapeutic targets in the early stages of clinical disease.
In addition I have also been involved in projects analysing T cell and B cell repopulation following alemtuzumab therapy; dissecting the mechanism of Th17 differentiation; and assessing Tregs in rheumatoid arthritis patients.
I co-supervise PhD and MRes
I lecture on the 'Current Research Trends in Musculoskeletal Disease' MRes module
- Bell GM, Anderson AE, Diboll J, Reece R, Eltherington O, Harry RA, Fouweather T, MacDonald C, Chadwick T, McColl EM, Dunn J, Dickinson AM, Hilkens CMU, Isaacs JD. Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis. Annals of the Rheumatic Diseases 2017, 76(1), 227-234.
- Anderson AE, Pratt AG, Sedhom MA, Doran JP, Routledge C, Hargreaves B, Brown PB, LeCao KA, Isaacs JD, Thomas R. IL-6-driven STAT signalling in circulating CD4+ lymphocytes is a marker for early anti-citrullinated peptide antibody-negative rheumatoid arthritis. Annals of the Rheumatic Diseases 2016, 75, 466-473.
- Anderson AE, Lorenzi AR, Pratt A, Wooldridge T, Diboll J, Hilkens CM, Isaacs JD. Immunity 12 years after alemtuzumab in RA: CD5+ B-cell depletion, thymus-dependent T-cell reconstitution and normal vaccine responses. Rheumatology 2012, 51(8), 1397-1406.
- Anderson AE, Swan DJ, Sayers BL, Harry RA, Patterson AM, von Delwig A, Robinson JH, Isaacs JD, Hilkens CM. LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells. Journal of Leukocyte Biology 2009, 85(2), 243-250.
- Anderson AE, Mackerness KJ, Aizen M, Carr VA, Nguyen D, Du Pre F, Durham SR, Robinson DS. Seasonal changes in suppressive capacity of CD4 CD25 T cells from patients with hayfever are allergen-specific and may result in part from expansion of effector T cells among the CD25 population. Clinical & Experimental Allergy 2009, 39(11), 1693-1699.
- Anderson AE, Sayers BL, Haniffa MA, Swan DJ, Diboll J, Wang XN, Isaacs JD, Hilkens CMU. Differential regulation of naïve and memory CD4+ T cells by alternatively activated dendritic cells. Journal of Leukocyte Biology 2008, 84(1), 124-133.
- Anderson AE, Worku ML, Khamri W, Bamford KB, Walker MM, Thursz MR. TLR9 polymorphisms determine murine lymphocyte responses to Helicobacter: Results from a genome-wide scan. European Journal of Immunology 2007, 37(6), 1548-1561.
- Purvis HA, Anderson AE, Young DA, Isaacs JD, Hilkens CMU. A Negative Feedback Loop Mediated by STAT3 Limits Human Th17 Responses. Journal of Immunology 2014, 193(3), 1142-1150.
- Brodlie M, McKean MC, Johnson GE, Anderson AE, Hilkens CM, Fisher AJ, Corris PA, Lordan JL, Ward C. Raised interleukin-17 is immunolocalised to neutrophils in cystic fibrosis lung disease. European Respiratory Journal 2011, 37(6), 1378-1385.
- Purvis HA, Stoop JN, Mann J, Woods S, Kozijn AE, Hambleton S, Robinson JH, Isaacs JD, Anderson AE, Hilkens CMU. Low-strength T-cell activation promotes Th17 responses. Blood 2010, 116(23), 4829-4837.
- Harry RA, Anderson AE, Isaacs JD, Hilkens CM. Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Annals of the Rheumatic Diseases 2010, 69(11), 2042-2050.
- Lorenzi A, Morgan TA, Anderson A, Catterall J, Patterson AM, Foster HE, Isaacs JD. Thymic function in juvenile idiopathic arthritis. Annals of the Rheumatic Diseases 2009, 68(6), 983-900.
- Khamri W, Worku ML, Anderson AE, Walker MM, Hawgood S, Reid KBM, Clark HW, Thursz MR. Helicobacter infection in the surfactant protein D-deficient mouse. Helicobacter 2007, 12(2), 112-123.
- Pratt AG, Anderson AE, Carmody RJ, Isaacs JD. Bcl-3 in CD4+ T Cell–Mediated Rheumatoid Arthritis Pathogenesis: Comment on the Article by Meguro et al. Arthritis and Rheumatology 2016, 68(3), 770-771.
- Cooles FA, Isaacs JD, Anderson AE. Treg Cells in Rheumatoid Arthritis: An Update. Current Rheumatology Reports 2013, 15(9), 1-9.
- Vila J, Isaacs JD, Anderson AE. Regulatory T cells and autoimmunity. Current Opinion in Hematology 2009, 16(4), 274-279.
- Anderson AE, Isaacs JD. Tregs and rheumatoid arthritis. Acta Reumatológica Portuguesa 2008, 33(1), 17-33.
- Al-momani H, Perry A, Jones R, Bourke S, Doe S, Perry J, Anderson A, Forrest T, Forrest I, Griffin M, Brodlie M, Pearson J, Ward C. Nontuberculous mycobacteria in gastrostomy fed patients with cystic fibrosis. Scientific Reports 2017, 7, 46546.
- McGovern A, Schoenfelder S, Martin P, Massey J, Duffus K, Plant D, Yarwood A, Pratt AG, Anderson AE, Isaacs JD, Diboll J, Thalayasingam N, Ospelt C, Barton A, Worthington J, Fraser P, Eyre S, Orozco G. Capture Hi-C identifies a novel causal gene, IL20RA, in the pan-autoimmune genetic susceptibility region 6q23. Genome Biology 2016, 17, 212.
- Cooles FAH, Anderson AE, Drayton T, Harry RA, Diboll J, Munro L, Thalayasingham N, Ostor AJK, Isaacs JD. Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies. Arthritis Research & Therapy 2016, 18, 302.
- Lord P, Spiering R, Aguillón JC, Anderson AE, Appel S, Benitez-Ribas D, ten-Brinke A, Broere F, Cools N, Cuturi MC, Diboll J, Geissler EK, Giannoukakis N, Gregori S, van-Ham SM, Lattimer S, Marshall L, Harry RA, Hutchinson JA, Isaacs JD, Joosten I, van-Kooten C, López-Díaz-de-Cerio A, Nikolic T, Barbaros-Oral H, Sofronic-Milosavljevic L, Ritter T, Riquelme P, Thomson AW, Trucco M, Vives-Pi M, Martinez-Caceres E, Hilkens CM. Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies. PeerJ 2016, 4, 1-14.
- Anderson AE, Swan DJ, Wong OY, Buck M, Eltherington O, Harry RA, Patterson AM, Pratt AG, Reynolds G, Doran JP, Kirby JA, Isaacs JD, Hilkens CM. Tolerogenic dendritic cells generated with dexamethasone and vitamin D3 regulate rheumatoid arthritis CD4+ T-cells partly via TGF-β1. Clinical & Experimental Immunology 2016, (ePub ahead of Print).